HSC and miRNA Regulation with Implication for Foetal Haemoglobin Induction in Beta Haemoglobinopathies
Chinwe Okeke1, Ufele Silas1, Obiageli Nnodu2
1Department of Medical Laboratory Science, Faculty of Health Science and Technology, University of Nigeria, Nsukka, Nigeria.
Insights
MicroRNAs (miRNAs) are key regulators in hematopoietic stem cells, influencing cell fate and hemoglobin production. Understanding their role offers potential new therapies for sickle cell disease and other beta-hemoglobinopathies.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Sickle cell disease (SCD) is a prevalent global hemoglobinopathy, disproportionately affecting sub-Saharan Africa with high child mortality.
- Fetal hemoglobin (HbF) production is crucial for managing SCD, highlighting the need for strategies to control globin gene expression.
- MicroRNAs (miRNAs) play vital roles in hematopoietic stem cell (HSC) differentiation, stemness maintenance, and gene regulation.
Purpose of the Study:
- To review the involvement of miRNAs in cell fate decisions and hemoglobin induction pathways.
- To explore the therapeutic potential of miRNAs for beta-hemoglobinopathies.
Main Methods:
- Literature review focusing on miRNA involvement in stem cell biology and hemoglobinopathies.
- Analysis of miRNA regulatory mechanisms in hematopoietic stem cells.
- Examination of miRNA-based therapeutic strategies.
Main Results:
- miRNAs are integral to HSC differentiation and gene expression modulation.
- miRNAs can reprogram somatic cells toward pluripotency, indicating potential for cell editing.
- Specific miRNAs are emerging as promising therapeutic targets for beta-hemoglobinopathies.
Conclusions:
- miRNA research offers a promising avenue for developing novel therapies for sickle cell disease and related disorders.
- Targeting miRNA pathways could lead to effective strategies for controlling globin gene expression and improving treatment outcomes for hemoglobinopathies.
Abstract:
Sickle cell disease (SCD) is one of the most common haemoglobinopathies worldwide, with up to 70 % of global SCD annual births occurring in sub-Saharan Africa. Reports have shown that 50 to 80 % of affected children in these countries die annually. Efforts geared towards understanding and controlling HbF production in SCD patients could lead to strategies for effective control of globin gene expression and therapeutic approaches that could be beneficial to individuals with haemoglobinopathies. Hemopoietic stem cells (HSCs) are characterized by a specific miRNA signature in every state of differentiation. The role of miRNAs has become evident both in the maintenance of the "stemness" and in the early induction of differentiation by modulation of the expression of the master pluripotency genes and during early organogenesis. miRNAs are extra regulatory mechanisms in hematopoietic stem cells (HSCs) via influencing transcription profiles together with transcript stability. miRNAs have been reported to be used to reprogram primary somatic cells toward pluripotency. Their involvement in cell editing holds the potential for therapy for many genetic diseases. This review provides a snapshot of miRNA involvement in cell fate decisions, haemoglobin induction pathway, and their journey as some emerge prime targets for therapy in beta haemoglobinopathies.
More Related Videos
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:22MicroRNAs
01:24Regulation of Angiogenesis and Blood Supply
01:23Regulation of Expression at Multiple Steps
01:30General Transcription Factors
02:16Transcription Factors